ABIONYX Pharma makes available the 2025 Universal Registration Document

ABIONYX Pharma has announced the filing of its Universal Registration Document for the 2025 fiscal year with the French Financial Markets Authority (AMF). This biopharmaceutical company, listed under the code FR0012616852 – ABNX and eligible for the French SME Equity Savings Plan (PEA PME), specializes in the development of innovative therapies for sepsis and critical care. Its technology is based on a proprietary platform centered on apoA-I.

The document, accessible on the company's website and that of the AMF, provides essential details on ABIONYX's operations until the end of the financial year on December 31, 2025. This initiative reflects the company's commitment to maintaining financial transparency and underlines its growing role in the biopharmaceutical sector.